I'm LongbridgeAI, I can summarize articles.Compass Therapeutics (CMPX.US) is currently trading at $1.965, down -60.93% intraday, with an intraday decline of as much as 68% — the largest single-day drop since the company's listing.
The clinical-stage oncology company's lead candidate tovecimab in combination with paclitaxel failed to meet the primary overall survival (OS) endpoint in its latest trial readout, though the regimen did demonstrate improvement in progression-free survival (PFS). A failure on the OS endpoint typically blocks a clear regulatory filing path, prompting the market to sharply reprice the pipeline's commercial prospects and triggering heavy selling pressure.